Navigation Links
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
Date:4/9/2009

cal trial application with the SFDA in 2009 in order to commence human dosing. The Company holds the development rights to this first-of-its-kind vaccine and intends to submit the patent application for this vaccine in China in 2009. We anticipate that this vaccine should become a flagship product given the severity of recent hand, foot and mouth disease outbreak in China and other countries. As the developer of a vaccine against hand, foot and mouth disease, Sinovac is well positioned to address this global unmet medical need as cases continue to be reported in China and neighboring countries. Sinovac is proud to take a leadership position, as we did with Panflu, to benefit China and the world by developing and manufacturing high quality, novel vaccines," concluded Mr. Yin.

Twelve Months Ended December 31, 2008

For the twelve months ended December 31, 2008, sales reached $46.5 million, compared to $33.5 million for the full year 2007, representing 39% growth.

During the twelve months ended December 31, 2008, Sinovac sold 6.93 million doses of Healive, compared to 5.12 million doses for the same period in 2007. Sinovac sold 1.56 million doses of Anflu during the full year 2008, compared to 1.59 million doses for the same period of the prior year. The Company sold 255,000 doses of Bilive during the 2008 period, compared to 15,684 doses in the prior year period. For the first twelve months of 2008, Healive, Anflu, and Bilive as a percentage of sales represented 88%, 9% and 3%, respectively.

Gross profit for twelve months ended December 31, 2008 was $36.6 million, with a gross margin of 79%, compared to $27.0 million, or 81%, for the same period of 2007.

Total operating expenses for the twelve months ended December 31, 2008 were $21 million, compared to $13.6 million for the same period 2007. Selling, general and administrative expenses for the twelve months ended Decembe
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
2. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
3. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
4. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
5. Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
6. Sinovac Releases Statement on Healive Vaccine Suspension
7. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
8. Sinovac Named to Deloitte Technology Fast 50 China
9. Sinovac to Participate in Two Upcoming Investor Conferences
10. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
11. Sinovac Biotech Holds 2007 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... December 19, 2014 In contrast to ... LEDs with various colors, Valoya uses proprietary LED technology ... offers best possible uniformity which is critical in low ... high spectral accuracy throughout its lifetime which is up ... tubes. , "The investment cost was clearly higher ...
(Date:12/19/2014)... 2014 Egenix, Inc. is pleased to announce that ... the Board, to succeed Donald Fresne ; Mr. Fresne ... as a member of the Board.  In recognition of the ... company over almost twenty years, the Board designated Mr. Fresne ... has established a Search Committee to find a suitable replacement ...
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... Committee Recommendation in European UnionSAN MATEO, Calif., March 19 ... biopharmaceutical company focused on developing and commercializing novel pain ... call on Friday, March 20, 2009 at 9:00 a.m. ... year-end 2008 results and the European Medicines Agency,s (EMEA) ...
... Solutions, a global life sciences technology solutions company ... that one of the world,s largest pharmaceutical companies ... System. This system provides a powerful, flexible ... lifecycle... from proposal to publication... helping to ensure ...
... will allow the recycling and conversion of 60% ... 19 /PRNewswire/ - Enerkem Inc., a leading advanced ... its plans to build and operate a second-generation ... In addition, the company announced the signature of ...
Cached Biology Technology:NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 2NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 3NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 4Top Ten Pharma Company Deploys MedNet Solutions' Investigator Initiated Trial Management System 2Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi 2Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi 3
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a ... that its U.are.U ® fingerprint readers have been ... in Central Mexico . The bakery ... to eliminate payroll issues caused by employees clocking in ... the U.are.U fingerprint readers, Montparnasse relied on paper timecards ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... release is available in German . ... and oxygen in order to survive. For this reason, a tumour ... to the blood circulation. In doing this, it is supported by ... neutrophils, which are supposed to protect the body against pathogens. ...
... poisoning in the news, including a recent event that led ... drives home the need for better bacterial detection long before ... the horizon is a new approach for pathogen screening that ... the technique in the ACS journal Analytical Chemistry . ...
... Nutrition Research Centre (CNRC) -- a $20 million ... (A*STAR) and National University Health Systems (NUHS) -- ... conduct nutritional studies to understand the causes of metabolic ... and formulate diets that can reduce the risks of ...
Cached Biology News:Jamming in tumors 2Asia's first under-1-roof Nutritional Research Centre set up in Singapore 2Asia's first under-1-roof Nutritional Research Centre set up in Singapore 3Asia's first under-1-roof Nutritional Research Centre set up in Singapore 4
... Peptide microarrays containing peptidomimetics built on ... on-chip synthesis platform. These microarrays are ... Custom Peptide Microarray Service. ... is completely customer specified. Thousands of ...
... are custom designed to meet your needs. ... 8,455 features per array (2 arrays/1" x ... array (1 array/slide). Features ... - This extended length delivers higher sensitivity ...
... Chemicon Select Tissue Arrays are intended ... individual tissues were fixed in neutral buffered ... identification and diagnosis was performed by certified ... their paraffin blocks and relocated into a ...
... Chemicon Select Tissue Arrays are intended for ... tissues were fixed in neutral buffered formalin ... and diagnosis was performed by certified pathologists. ... paraffin blocks and relocated into a new ...
Biology Products: